These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 28518222)

  • 21. Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia.
    Chapman J; Geyer JT; Khanlari M; Moul A; Casas C; Connor ST; Fan YS; Watts JM; Swords RT; Vega F; Orazi A
    Mod Pathol; 2018 Mar; 31(3):429-441. PubMed ID: 29192651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of molecular profiling on the management of patients with myelofibrosis.
    Pastor-Galán I; Martín I; Ferrer B; Hernández-Boluda JC
    Cancer Treat Rev; 2022 Sep; 109():102435. PubMed ID: 35839532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Complex molecular genetic algorithm in the diagnosis of myeloproliferative neoplasms].
    Krähling T; Balassa K; Meggyesi N; Bors A; Csomor J; Bátai Á; Halm G; Egyed M; Fekete S; Reményi P; Masszi T; Tordai A; Andrikovics H
    Orv Hetil; 2014 Dec; 155(52):2074-81. PubMed ID: 25528320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Not Available].
    Mosca M; Vertenoeil G; Toppaldoddi KR; Plo I; Vainchenker W
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S16-28. PubMed ID: 27494969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib.
    Bjørn ME; Hasselbalch HC
    Expert Rev Hematol; 2017 May; 10(5):393-404. PubMed ID: 28402197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach.
    Iurlo A; Elli EM; Palandri F; Cattaneo D; Bossi A; Cortinovis I; Bucelli C; Orofino N; Brioschi F; Auteri G; Bianchi P; Fabris S; Isimbaldi G; Sabattini E; Baldini L; Gianelli U
    Hematol Oncol; 2019 Oct; 37(4):424-433. PubMed ID: 31359447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Calreticulin mutations in Chinese with primary myelofibrosis.
    Li B; Xu J; Wang J; Gale RP; Xu Z; Cui Y; Yang L; Xing R; Ai X; Qin T; Zhang Y; Zhang P; Xiao Z
    Haematologica; 2014 Nov; 99(11):1697-700. PubMed ID: 24997152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation.
    Mannina D; Gagelmann N; Badbaran A; Ditschkowski M; Bogdanov R; Robin M; Cassinat B; Heuser M; Shahswar R; Thol F; Beelen D; Kröger N
    Eur J Haematol; 2019 Dec; 103(6):552-557. PubMed ID: 31446640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha.
    Stauffer Larsen T; Iversen KF; Hansen E; Mathiasen AB; Marcher C; Frederiksen M; Larsen H; Helleberg I; Riley CH; Bjerrum OW; Rønnov-Jessen D; Møller MB; de Stricker K; Vestergaard H; Hasselbalch HC
    Leuk Res; 2013 Sep; 37(9):1041-5. PubMed ID: 23827351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autoimmune Myelofibrosis: Clinical Features, Course, and Outcome.
    Piatek CI; Vergara-Lluri ME; Pullarkat V; Siddiqi IN; O'Connell C; Brynes RK; Feinstein DI
    Acta Haematol; 2017; 138(3):129-137. PubMed ID: 28866671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SRSF2 and U2AF1 mutations in primary myelofibrosis are associated with JAK2 and MPL but not calreticulin mutation and may independently reoccur after allogeneic stem cell transplantation.
    Bartels S; Lehmann U; Büsche G; Schlue J; Mozer M; Stadler J; Triviai I; Alchalby H; Kröger N; Kreipe H
    Leukemia; 2015 Jan; 29(1):253-5. PubMed ID: 25231745
    [No Abstract]   [Full Text] [Related]  

  • 34. Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms.
    Skov V; Thomassen M; Kjær L; Ellervik C; Larsen MK; Knudsen TA; Kruse TA; Hasselbalch HC
    PLoS One; 2022; 17(6):e0270669. PubMed ID: 35771847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.
    Tefferi A; Lasho TL; Begna KH; Patnaik MM; Zblewski DL; Finke CM; Laborde RR; Wassie E; Schimek L; Hanson CA; Gangat N; Wang X; Pardanani A
    N Engl J Med; 2015 Sep; 373(10):908-19. PubMed ID: 26332545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.
    Verger E; Cassinat B; Chauveau A; Dosquet C; Giraudier S; Schlageter MH; Ianotto JC; Yassin MA; Al-Dewik N; Carillo S; Legouffe E; Ugo V; Chomienne C; Kiladjian JJ
    Blood; 2015 Dec; 126(24):2585-91. PubMed ID: 26486786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.
    Finazzi MC; Carobbio A; Cervantes F; Isola IM; Vannucchi AM; Guglielmelli P; Rambaldi A; Finazzi G; Barosi G; Barbui T
    Leukemia; 2015 May; 29(5):1209-10. PubMed ID: 25482134
    [No Abstract]   [Full Text] [Related]  

  • 38. [Interferon-alpha-2b induces molecular responses of patients with polycythemia vera and its post-polycythemic myelofibrosis].
    Bai J; Xue YP; Zhang L; Li CH; Fan DM; Li B; Xu SC; Li DP; Sun XJ; Jiang B; Yang RC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):444-9. PubMed ID: 21518505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Important Pathologic Considerations for Establishing the Diagnosis of Myelofibrosis.
    Salama ME
    Hematol Oncol Clin North Am; 2021 Apr; 35(2):267-278. PubMed ID: 33641868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversible bone marrow aplasia induced by pegylated interferon-α-2a therapy in a patient with primary myelofibrosis.
    Mainali NR; Bhatt VR; Kedia S; Krishnamurthy J; Wake LM; Akhtari M
    J Oncol Pharm Pract; 2014 Oct; 20(5):386-92. PubMed ID: 24067929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.